Viracta Therapeutics (VIRX)
(Delayed Data from NSDQ)
$0.84 USD
-0.01 (-1.36%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $0.83 -0.01 (-0.75%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Cash flow Statements
Fiscal Year End for Viracta Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -51.06 | -49.20 | -114.76 | -21.61 | -23.33 |
Depreciation/Amortization & Depletion | -1.56 | -0.42 | 0.18 | -0.01 | 0.05 |
Net Change from Assets/Liabilities | 5.08 | 0.61 | 1.68 | -0.32 | -0.65 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 7.65 | 13.55 | 94.05 | 0.49 | 1.75 |
Net Cash From Operating Activities | -39.89 | -35.46 | -18.85 | -21.44 | -22.19 |
Property & Equipment | -0.14 | -0.05 | -0.25 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 17.14 | 0.00 | 0.00 |
Investments | 15.14 | -53.82 | 0.00 | 16.41 | -16.29 |
Other Investing Activities | 0.00 | 0.00 | -4.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 15.00 | -53.87 | 12.89 | 16.41 | -16.29 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.44 | 2.56 | 62.66 | 12.68 | 45.08 |
Issuance (Repayment) of Debt | 0.00 | 19.99 | -0.23 | 0.00 | 5.45 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | -5.50 | -7.50 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.44 | 22.54 | 62.43 | 7.18 | 43.04 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -24.46 | -66.78 | 56.47 | 2.15 | 4.57 |
Cash at Beginning of Period | 36.77 | 103.55 | 47.09 | 18.26 | 13.70 |
Cash at End of Period | 12.32 | 36.77 | 103.55 | 20.41 | 18.26 |
Diluted Net EPS | -1.32 | -1.30 | -3.60 | -5.36 | -9.45 |
Fiscal Year End for Viracta Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -51.06 | -37.29 | -24.69 | -12.21 |
Depreciation/Amortization & Depletion | NA | -1.56 | -1.21 | -0.82 | -0.40 |
Net Change from Assets/Liabilities | NA | 5.08 | 2.77 | 2.09 | -0.84 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 7.65 | 5.87 | 4.09 | 2.11 |
Net Cash From Operating Activities | NA | -39.89 | -29.87 | -19.33 | -11.34 |
Property & Equipment | NA | -0.14 | -0.14 | -0.19 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 15.14 | 5.87 | -3.18 | -7.35 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 15.00 | 5.73 | -3.37 | -7.35 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.44 | 0.22 | 0.22 | 0.02 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 0.44 | 0.22 | 0.22 | 0.02 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -24.46 | -23.92 | -22.48 | -18.67 |
Cash at Beginning of Period | NA | 36.77 | 36.77 | 36.77 | 36.77 |
Cash at End of Period | NA | 12.32 | 12.86 | 14.29 | 18.10 |
Diluted Net EPS | NA | -0.35 | -0.33 | -0.32 | -0.32 |